REG - Adv Medical Solutns. - Results of Annual General Meeting

Advanced Medical SolutionsAnnouncement

12/06/2024 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240612:nRSL1866Sa&default-theme=true

RNS Number : 1866S  Advanced Medical Solutions Grp PLC  12 June 2024

12 June 2024

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Results of Annual General Meeting

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, announces that at the
Company's Annual General Meeting held today at 11 am at the Offices of
Investec Bank plc, 30 Gresham Street, London, EC2V 7QP, all resolutions were
duly passed. Further details of each of the resolutions are set out in the
Notice of Meeting, which was sent to shareholders on 13 May 2024.

 

The poll results were as follows.

 

 Resolution  Title                      For                           For %    Against                                         Against %  Total Votes               % Issued Capital
 1           FINANCIAL STATEMENTS                136,356,167          99.99%                      9,361                        0.01%             136,365,528        62.69%
 2           REMUNERATION REPORT                 134,014,363          98.45%                2,107,730                          1.55%             136,122,093        62.58%
 3           AUDITOR REMUNERATION                133,257,997          97.65%                3,210,036                          2.35%             136,468,033        62.74%
 4           RE-ELECT L SHANAHAN                 129,648,691          95.22%                6,506,705                          4.78%             136,155,396        62.60%
 5           RE-ELECT G COOK                     129,863,105          95.16%                6,601,163                          4.84%             136,464,268        62.74%
 6           RE-ELECT D LE FORT                  130,840,531          95.88%                5,623,737                          4.12%             136,464,268        62.74%
 7           RE-ELECT C MEREDITH                 132,798,078          97.31%                3,666,187                          2.69%             136,464,265        62.74%
 8           RE-ELECT E JOHNSON                  136,218,616          99.82%                   245,652                         0.18%             136,464,268        62.74%
 9           FINAL DIVIDEND                      136,505,565          100.00%                        516                       0.00%             136,506,081        62.76%
 10          Deferred Bonus Plan                 136,377,375          99.92%                   113,837                         0.08%             136,491,212        62.75%
 11          Long Term Incentive Plan            135,984,889          99.63%                   506,310                         0.37%             136,491,199        62.75%
 12          Deferred Share Bonus Plan           136,190,086          99.78%                   300,213                         0.22%             136,490,299        62.75%
 13          ALLOT SHARES*                       135,883,826          99.56%                   600,189                         0.44%             136,484,015        62.75%
 14          PRE-EMPTION RIGHTS*                 134,775,458          98.75%                1,708,671                          1.25%             136,484,129        62.75%
 15          PURCHASE SHARES*                 108,148,575             99.92%                    82,427                         0.08%             108,231,002        49.76%

*  Special Resolution

 Notes:

 1.  Votes "For" and "Against" are expressed as a percentage of votes
 received.

 2.  A "Vote withheld" is not a vote in law and is not counted in the
 calculation of the votes "For" or "Against" a resolution.

 3.  Total number of shares in issue at close of business on 7 June =
 217,508,089 shares. 62.75% of the voting capital was instructed.

 

- End -

 

 

 

 

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc            Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 ICR Consilium                                   Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Lucy Featherstone           AMS@icrhealthcare.com

 Investec Bank PLC (NOMAD & Broker)              Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 HSBC Bank plc (Broker)                          Tel: 44 (0) 20 7991 8888
 Sam McLennan / Joe Weaving / Stephanie Cornish

 

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®) and Seal-G(®). AMS also supplies wound care dressings such
as silver alginates, alginates and foams through its ActivHeal(®) brand as
well as under white label. Since 2019, the Group has made six acquisitions:
Sealantis, an Israeli developer of innovative internal sealants; Biomatlante,
a French developer and manufacturer of surgical biomaterials, Raleigh, a
leading UK coater and converter of woundcare and bio-diagnostics materials,
AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish
tissue adhesives specialist, and Syntacoll, a German specialist in
collagen-based absorbable surgical implants.

 

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the
Czech Republic and Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, the Czech Republic and Russia. The Group has
R&D innovation hubs in the UK, Ireland, Germany, France and Israel.
Established in 1991, the Group has more than 900 employees. For more
information, please see  www.admedsol.com (http://www.admedsol.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSFWFEEELSELM